Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
106M
-
Number of holders
-
73
-
Total 13F shares, excl. options
-
26.6M
-
Shares change
-
+3.01M
-
Total reported value, excl. options
-
$513M
-
Value change
-
+$61.9M
-
Put/Call ratio
-
0.49
-
Number of buys
-
47
-
Number of sells
-
-25
-
Price
-
$19.26
Significant Holders of Amylyx Pharmaceuticals, Inc. - COMMON STOCK (AMLX) as of Q2 2022
102 filings reported holding AMLX - Amylyx Pharmaceuticals, Inc. - COMMON STOCK as of Q2 2022.
Amylyx Pharmaceuticals, Inc. - COMMON STOCK (AMLX) has 73 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26.6M shares
of 106M outstanding shares and own 25.03% of the company stock.
Largest 10 shareholders include VIKING GLOBAL INVESTORS LP (7.17M shares), PERCEPTIVE ADVISORS LLC (3.54M shares), BOXER CAPITAL, LLC (2.2M shares), Bain Capital Life Sciences Investors, LLC (1.95M shares), VANGUARD GROUP INC (994K shares), Rock Springs Capital Management LP (974K shares), Verition Fund Management LLC (950K shares), TYBOURNE CAPITAL MANAGEMENT (HK) LTD (769K shares), CITADEL ADVISORS LLC (754K shares), and BlackRock Inc. (709K shares).
This table shows the top 73 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.